Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT02695680
Official study title

Lung SBRT Motion Management (GCC 1619)

Study summary

Real-time optical surface monitoring data will be acquired from 44 human patients with primary or metastatic lung lesions during and after their 4DCT scan (standard-of-care at our institution). A patient-specific 4D model will be developed using the raw 4DCT projections time-correlated with real-time surface monitoring. In addition, before delivering each dose fraction (3 - 5 for lung SBRT), we will acquire three 15s kV fluoroscopic image acquisitions, time-correlated with optical surface monitoring. The acquisitions will be distributed over three well-spaced beam angles, e.g., every 4th angle for a 12-field plan.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 8, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of Maryland, Baltimore

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of Maryland, Baltimore
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Metastatic or stage IV→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Eligible disease(s)/stage(s) - Patients with primary or metastatic lung lesions to be treated using stereotactic body radiotherapy (SBRT) will be eligible for this study. 2. Allowable type and amount of prior therapy - Any types and amounts of prior therapy will be allowed for this study. 3. Age restriction and/or gender/ethnic restrictions - Patients must be greater than or equal to 18 years of age. There are no gender or ethnic restrictions. 4. Life expectancy restrictions - None. 5. ECOG or Karnofsky Performance Status - Karnofsky performance status of 50 or greater 6. Requirements for organ and marrow function - None. 7. Ability to understand and the willingness to sign a written informed consent document. 8. Tumor motion \> 5 mm, maximum GTV dimension \< 50 mm - per guidelines established by the AAPM Task Group 7612 and RTOG 0236.13

Reasons someone may not be able to joinExclusion criteria

1. Children (age \<18) 2. Women who are pregnant or trying to get pregnant 3. Pain in supine position 4. Karnofsky performance status \< 50

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Ummc MsgccBaltimore, Maryland
  • Upper Chesapeake HealthBel Air, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 8, 2024. Always confirm current availability with the study team.

View original record ↗